Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Robson

Showing results (131-140 of 210) with videos related to

Pageof 21
Sort By:
Oncotarget|June 5, 2018
The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survivalUrszula L McClurg, Mahsa Azizyan, Daniel T Dransfield, et al.
Molecular Cancer Therapeutics|June 3, 2010
Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibitionCarolyn Wiltshire, Babloo L Singh, Jacqueline Stockley, et al.
The Prostate|July 3, 2013
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infectionClaire L Townes, Ased Ali, Naomi Gross, et al.
Human Pathology|May 23, 2008
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancerS J Wilkinson, A Kucukmetin, P Cross, et al.
BJU International|August 18, 2012
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?Haley L Bennett, Jacqueline Stockley, Janis T Fleming, et al.
British Journal of Cancer|January 19, 2005
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancerB Gowardhan, D A Douglas, M E Mathers, et al.
Oncotarget|December 10, 2013
A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferationJennifer Munkley, Prabhakar Rajan, Nicholas P Lafferty, et al.
Biochemical Pharmacology|February 18, 1992
Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin CP R Hoban, C N Robson, S M Davies, et al.
Cancer Research|August 1, 1990
Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditionsP R Hoban, M I Walton, C N Robson, et al.
The Journal of Biological Chemistry|September 24, 2013
Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptorUrszula L Burska, Victoria J Harle, Kelly Coffey, et al.
Pageof 21

Showing results (131-140 of 210) with videos related to

Sort By:
Pageof 21
Oncotarget|June 5, 2018
The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survivalUrszula L McClurg, Mahsa Azizyan, Daniel T Dransfield, et al.
Molecular Cancer Therapeutics|June 3, 2010
Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibitionCarolyn Wiltshire, Babloo L Singh, Jacqueline Stockley, et al.
The Prostate|July 3, 2013
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infectionClaire L Townes, Ased Ali, Naomi Gross, et al.
Human Pathology|May 23, 2008
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancerS J Wilkinson, A Kucukmetin, P Cross, et al.
BJU International|August 18, 2012
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?Haley L Bennett, Jacqueline Stockley, Janis T Fleming, et al.
British Journal of Cancer|January 19, 2005
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancerB Gowardhan, D A Douglas, M E Mathers, et al.
Oncotarget|December 10, 2013
A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferationJennifer Munkley, Prabhakar Rajan, Nicholas P Lafferty, et al.
Biochemical Pharmacology|February 18, 1992
Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin CP R Hoban, C N Robson, S M Davies, et al.
Cancer Research|August 1, 1990
Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditionsP R Hoban, M I Walton, C N Robson, et al.
The Journal of Biological Chemistry|September 24, 2013
Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptorUrszula L Burska, Victoria J Harle, Kelly Coffey, et al.
Pageof 21